Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07129993 | Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: DS1062-328
• Study Type: interventional
• Target: 630
• Locations: 7 countries
• Sites: 79

Brief Summary

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommended Phase 3 dose (RP3D) will be identified when the data allow sufficient assessment of activity, safety, and tolerability. The Phase 3 part will start contingent upon the assessment in the Phase 2 part, taking into consideration the totality of information.

Conditions

Urothelial Cancer; Bladder Cancer

Keywords

Urothelial Carcinoma; Dato-DXd; TROPION; DS-1062a; Datopotamab Deruxtecan

Outcome Measures

Primary Outcomes (3)

• Overall Response Rate - Part A (Phase 2)

  Overall Response Rate (ORR) is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or confirmed Partial Response (PR). As assessed by investigator per RECIST v1.1

  From Phase 2 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 34 months

• Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)

  Progression Free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first. As assessed by BICR per RECIST v1.1

  From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months

• Overall Survival - Part B (Phase 3)

  Overall Survival (OS) is defined as the time from randomization to death due to any cause.

  From Phase 3 randomization to death due to any cause, up to approximately 38 months

Secondary Outcomes (3)

• Duration of Response - Part A (Phase 2)

  From the date of first documentation of objective tumor response to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first in Phase 2, up to approximately 34 months

• Progression Free Survival as Assessed by Investigator - Part B (Phase 3)

  From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months

• Overall Response Rate - Part B (Phase 3)

  From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months

Study Arms (4)

Part A (Phase 2): Dato-DXd, 4 mg/kg with Platinum

EXPERIMENTAL

Participants will receive Dato-DXd in combination with platinum (carboplatin or cisplatin). The RP3D will be determined using data collected from Part A.

Drug: Dato-DXd; Drug: Carboplatin; Drug: Cisplatin

Part A (Phase 2): Dato-DXd, 6 mg/kg with Platinum

EXPERIMENTAL

Participants will receive Dato-DXd in combination with platinum (carboplatin or cisplatin). The RP3D will be determined using data collected from Part A.

Drug: Dato-DXd; Drug: Carboplatin; Drug: Cisplatin

Part B (Phase 3): Dato-DXd, RP3D with Platinum

EXPERIMENTAL

Participants will receive Dato-DXd at the RP3D in combination with platinum (carboplatin or cisplatin).

Drug: Dato-DXd; Drug: Carboplatin; Drug: Cisplatin

Part B (Phase 3): Gemcitabine with Platinum

ACTIVE COMPARATOR

Participants will receive Gemcitabine in combination with platinum (carboplatin or cisplatin).

Drug: Carboplatin; Drug: Cisplatin; Drug: Gemcitabine

Interventions

Dato-DXd DRUG

Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B

Also known as: Datopotamab Deruxtecan

Part A (Phase 2): Dato-DXd, 4 mg/kg with Platinum; Part A (Phase 2): Dato-DXd, 6 mg/kg with Platinum; Part B (Phase 3): Dato-DXd, RP3D with Platinum

Carboplatin DRUG

Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL

Part A (Phase 2): Dato-DXd, 4 mg/kg with Platinum; Part A (Phase 2): Dato-DXd, 6 mg/kg with Platinum; Part B (Phase 3): Dato-DXd, RP3D with Platinum; Part B (Phase 3): Gemcitabine with Platinum

Cisplatin DRUG

Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m2

Part A (Phase 2): Dato-DXd, 4 mg/kg with Platinum; Part A (Phase 2): Dato-DXd, 6 mg/kg with Platinum; Part B (Phase 3): Dato-DXd, RP3D with Platinum; Part B (Phase 3): Gemcitabine with Platinum

Gemcitabine DRUG

Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m2 on Day 1 and 8 of every 3 week cycle.

Part B (Phase 3): Gemcitabine with Platinum

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult ≥18 years at the time the ICF is signed (if the legal age of consent is \> 18 years old, then follow the local regulatory requirements).
• Histologically or cytologically confirmed unresectable locally advanced (T4b, any N; or any T, N 2-3) or metastatic (any T, any N, M1) urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra.
• Participants with urothelial carcinoma (transitional cell) with squamous differentiation or mixed cell types are eligible if the histology is predominantly urothelial.
• Note 1: Urachal, small cell, and adenocarcinoma histology is not permitted.
• Note 2: Participants with la/mUC and a history of nonclinically active prostate cancer are allowed into the trial if:
• Participant does not have radiological metastasis of a proven prostate cancer.
• Participant with nonmetastatic prostate cancer do not have rising PSA (as determined using local testing by a validated or approved test method) defined as follows:
• Increase in PSA within 2 consecutive measurements separated by at least 1 week (completed within 4 weeks prior to consent or within Screening) and neither of the measurements with an absolute value above 2 ng/mL.
• Participant does not currently receive androgen deprivation therapy for the treatment of prostate cancer. • Must provide tumor tissue sample from archival tissue or newly obtained pretreatment biopsy for exploratory biomarker testing. Tumor tissue sample should not be collected from a lesion that was irradiated unless documentation can be provided confirming that the tumor tissue was collected at least 3 months after radiation and the lesion increased/appeared since radiation occurred. Tumor tissue must be of sufficient quantity (as defined in the laboratory manual).
• <!-- -->
• Archival tissue collected after the most recent anticancer treatment and within 12 months before the informed consent date is preferred. • Participant must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment. Participants eligible for cisplatin will receive cisplatin. If a participant received gemcitabine, carboplatin or cisplatin for early UC in the adjuvant/neoadjuvant setting, ≥1 year must have passed since the last dose of these chemotherapy prior to the first dose of trial intervention. Participants only receive carboplatin if they are ineligible for cisplatin. Participants are cisplatin-ineligible if they meet any of the following criteria:
• <!-- -->
• GFR \<60 mL/min (GFR may be estimated by calculated CrCl using the Cockcroft-Gault formula, Modification of Diet in Renal Disease, or 24-hour urine)
• Participants with a GFR \<60 mL/min but ≥50 mL/min but have no other cisplatin ineligibility criteria (items b, c, and d) may be considered cisplatin-eligible based on the investigator's clinical judgment.
• NCI-CTCAE Grade ≥2 audiometric hearing loss

You may not qualify if:

• Has had prior systemic therapy other than the combination of EV and pembrolizumab for la/mUC. The following participants may be considered eligible after approval by the Sponsor's Medical Monitor or Sponsor's designee.
• a. Participant who progressed during or after treatments with assets that include either anti-Nectin 4 or vedotin payload (MMAE or other microtubule inhibitors) combined with PD1/PD-L1 inhibitors in 1L la/mUC.
• Treatment with any of the following:
• History of an allogeneic bone marrow or solid organ transplant.
• Concomitant treatment with any prohibited medications in this protocol.
• Prior TROP2 directed ADC therapy.
• Uncontrolled or significant cardiovascular disease, including:
• QTcF interval \>450 ms based on the average of triplicate 12-lead (ECG per local read) at Screening.
• Myocardial infarction within 6 months prior to randomization.
• Uncontrolled angina pectoris within 6 months prior to randomization.
• NYHA Class 3 or 4 congestive heart failure at Screening (See Section 10.3.2).
• Uncontrolled hypertension (resting systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg within 28 days before randomization that is not resolved despite maximal medical therapy).
• Has a history of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
• Has clinically severe pulmonary compromise as judged by the investigator resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.) or any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.), or prior complete pneumonectomy.
• Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤1 or baseline. Note: Participants may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade \>2 for at least 3 months prior to randomization and managed with standard of care treatment) which the investigator deems related to previous anticancer therapy, comprised of (including but not limited to):

Sponsors & Collaborators

• Daiichi Sankyo: lead
• AstraZeneca: collaborator

Study Sites (79)

Research Site

Fullerton, California, 92835, United States

ACTIVE NOT RECRUITING

Research Site

La Jolla, California, 92093, United States

ACTIVE NOT RECRUITING

Research Site

San Francisco, California, 94158, United States

ACTIVE NOT RECRUITING

Research Site

Aurora, Colorado, 80012, United States

ACTIVE NOT RECRUITING

Research Site

Orange City, Florida, 32763, United States

ACTIVE NOT RECRUITING

Research Site

St. Petersburg, Florida, 33701, United States

ACTIVE NOT RECRUITING

Research Site

Tamarac, Florida, 62269, United States

ACTIVE NOT RECRUITING

Research Site

Atlanta, Georgia, 30342, United States

ACTIVE NOT RECRUITING

Research Site

Locust Grove, Georgia, 30248, United States

ACTIVE NOT RECRUITING

Research Site

Effingham, Illinois, 62401, United States

ACTIVE NOT RECRUITING

Research Site

Niles, Illinois, 60714, United States

RECRUITING

Research Site

Peoria, Illinois, 61615, United States

RECRUITING

Research Site

Largo, Maryland, 20774, United States

ACTIVE NOT RECRUITING

Research Site

Grand Rapids, Michigan, 49546, United States

RECRUITING

Research Site

St Louis, Missouri, 63110, United States

ACTIVE NOT RECRUITING

Research Site

New York, New York, 10029, United States

ACTIVE NOT RECRUITING

Research Site

Raleigh, North Carolina, 27610, United States

ACTIVE NOT RECRUITING

Research Site

Portland, Oregon, 97227, United States

ACTIVE NOT RECRUITING

Research Site

Philadelphia, Pennsylvania, 19107, United States

ACTIVE NOT RECRUITING

Research Site

Myrtle Beach, South Carolina, 29572, United States

ACTIVE NOT RECRUITING

Research Site

Germantown, Tennessee, 38138, United States

ACTIVE NOT RECRUITING

Research Site

Nashville, Tennessee, 37203, United States

RECRUITING

Research Site

Austin, Texas, 33322, United States

ACTIVE NOT RECRUITING

Research Site

Dallas, Texas, 75246, United States

RECRUITING

Research Site

Dallas, Texas, 75390, United States

ACTIVE NOT RECRUITING

Research Site

Charlottesville, Virginia, 22908, United States

ACTIVE NOT RECRUITING

Research Site

Norfolk, Virginia, 23502-1871, United States

RECRUITING

Research Site

Spokane, Washington, 99208, United States

ACTIVE NOT RECRUITING

Research Site

Madison, Wisconsin, 53715, United States

ACTIVE NOT RECRUITING

Research Site

Krems, Austria

ACTIVE NOT RECRUITING

Research Site

Vienna, Austria

ACTIVE NOT RECRUITING

Research Site

Beijing, 100142, China

RECRUITING

Research Site

Chengdu, China

ACTIVE NOT RECRUITING

Research Site

Guangzhou, China

ACTIVE NOT RECRUITING

Research Site

Angers, 49055, France

ACTIVE NOT RECRUITING

Research Site

Bordeaux, 33075, France

RECRUITING

Research Site

Brest, France

RECRUITING

Research Site

Calais, France

ACTIVE NOT RECRUITING

Research Site

Cedex 10, France

RECRUITING

Research Site

Créteil, France

ACTIVE NOT RECRUITING

Research Site

Grenoble, France

ACTIVE NOT RECRUITING

Research Site

La Chaussée-Saint-Victor, France

ACTIVE NOT RECRUITING

Research Site

La Roche-sur-Yon, France

ACTIVE NOT RECRUITING

Research Site

Le Mans, France

RECRUITING

Research Site

Lyon, France

ACTIVE NOT RECRUITING

Research Site

Marseille, France

ACTIVE NOT RECRUITING

Research Site

Montpellier, France

RECRUITING

Research Site

Nantes, France

ACTIVE NOT RECRUITING

Research Site

Nîmes, France

ACTIVE NOT RECRUITING

Research Site

Paris, France

ACTIVE NOT RECRUITING

Research Site

Paris, France

RECRUITING

Research Site

Pierre-Bénite, 69310, France

ACTIVE NOT RECRUITING

Research Site

Poitiers, France

RECRUITING

Research Site

Quint-Fonsegrives, France

ACTIVE NOT RECRUITING

Research Site

Reims, France

ACTIVE NOT RECRUITING

Research Site

Saint-Etienne, France

RECRUITING

Research Site

Saint-Herblain, France

ACTIVE NOT RECRUITING

Research Site

Toulouse, France

ACTIVE NOT RECRUITING

Research Site

Vandœuvre-lès-Nancy, France

ACTIVE NOT RECRUITING

Research Site

Nürtingen, Germany

RECRUITING

Research Site

Naples, Italy

ACTIVE NOT RECRUITING

Research Site

Roma, Italy

ACTIVE NOT RECRUITING

Research Site

Rozzano, Italy

ACTIVE NOT RECRUITING

Research Site

Bunkyō City, 113-8519, Japan

ACTIVE NOT RECRUITING

Research Site

Bunkyō City, Japan

ACTIVE NOT RECRUITING

Research Site

Fukuoka, Japan

ACTIVE NOT RECRUITING

Research Site

Hirosaki-shi, Japan

ACTIVE NOT RECRUITING

Research Site

Kanazawa, Japan

ACTIVE NOT RECRUITING

Research Site

Kawasaki, Japan

ACTIVE NOT RECRUITING

Research Site

Kōtoku, 135-8550, Japan

ACTIVE NOT RECRUITING

Research Site

Kumamoto, Japan

ACTIVE NOT RECRUITING

Research Site

Nagoya, Japan

ACTIVE NOT RECRUITING

Research Site

Niigata, Japan

ACTIVE NOT RECRUITING

Research Site

Okayama, 700-8558, Japan

ACTIVE NOT RECRUITING

Research Site

Osaka, Japan

ACTIVE NOT RECRUITING

Research Site

Sapporo, Japan

ACTIVE NOT RECRUITING

Research Site

Shinjuku-ku, Japan

ACTIVE NOT RECRUITING

Research Site

Toyama, Japan

ACTIVE NOT RECRUITING

Research Site

Ube-shi, 755-8505, Japan

RECRUITING

MeSH Terms

Conditions

Urinary Bladder Neoplasms; Carcinoma, Transitional Cell

Interventions

Carboplatin; Cisplatin; Gemcitabine

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring

Central Study Contacts

Contact for Trial Information

CONTACT

908-992-6400; CTRinfo_us@daiichisankyo.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2025
• First Posted: August 19, 2025
• Study Start: September 26, 2025
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): January 22, 2030
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF
• Time Frame: Completed studies that have reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
• Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Locations

FR (25); AU (2); CN (3); US (29); DE (1); IT (3); JP (16)